Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer
Public ClinicalTrials.gov record NCT00394251. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-label, Randomized, Comparative Pilot Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of this study was to compare the safety of dose-dense ABI-007 (Abraxane) 260 mg/m\^2 or Taxol 175 mg/m\^2 given every 2 weeks following dose-dense Adriamycin plus Cytoxan (AC) chemotherapy. Bevacizumab was administered at 10 mg/kg every 2 weeks throughout chemotherapy, and then at 15 mg/kg every 3 weeks following chemotherapy.
Study identification
- NCT ID
- NCT00394251
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 197 participants
Conditions and interventions
Conditions
Interventions
- Adriamycin and Cytoxan (AC) Drug
- ABI-007 Drug
- Taxol Drug
- Bevacizumab Drug
- pegfilgrastim Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 1, 2006 (Actual)
- Primary completion
- Mar 1, 2007 (Actual)
- Completion
- Feb 1, 2008 (Actual)
- Last update posted
- Nov 25, 2019
2006 – 2008
United States locations
- U.S. sites
- 27
- U.S. states
- 14
- U.S. cities
- 26
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Birmingham | Alabama | 35205 | — |
| Not listed | Sedona | Arizona | 86336 | — |
| Not listed | Denver | Colorado | 80220 | — |
| Not listed | Torrington | Connecticut | 06790 | — |
| Not listed | Indianapolis | Indiana | 46227 | — |
| Not listed | Minneapolis | Minnesota | 55404 | — |
| Not listed | Columbia | Missouri | 65201 | — |
| Not listed | St Louis | Missouri | 63136 | — |
| Not listed | Henderson | Nevada | 89052 | — |
| Not listed | Raleigh | North Carolina | 27607 | — |
| Not listed | Eugene | Oregon | 97401 | — |
| Not listed | Greenville | South Carolina | 29615 | — |
| Not listed | Austin | Texas | 78731 | — |
| Not listed | Bedford | Texas | 76022 | — |
| Not listed | Dallas | Texas | 75231 | — |
| Not listed | Dallas | Texas | 75246 | — |
| Not listed | El Paso | Texas | 79915 | — |
| Not listed | Fort Worth | Texas | 76104 | — |
| Not listed | Fredericksburg | Texas | 78624 | — |
| Not listed | Houston | Texas | 77024 | — |
| Not listed | Longview | Texas | 75601 | — |
| Not listed | McAllen | Texas | 78503 | — |
| Not listed | Tyler | Texas | 75702 | — |
| Not listed | Waco | Texas | 76712 | — |
| Not listed | Fairfax | Virginia | 22031 | — |
| Not listed | Norfolk | Virginia | 23502 | — |
| Not listed | Vancouver | Washington | 98684 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00394251, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 25, 2019 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00394251 live on ClinicalTrials.gov.